Skip to content

A real-world study on the efficacy and safety of pyrotinib in the treatment of HER-2 positive breast cancer patients with brain metastases

A real-world study on the efficacy and safety of pyrotinib in the treatment of HER-2 positive breast cancer patients with brain metastases

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037995
Enrollment
Unknown
Registered
2020-09-08
Start date
2020-09-07
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

case series:Nil

Sponsors

Shandong Cancer Hospital and Institute
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with age >= 18 years old; 2. Patients with brain metastatic breast cancer confirmed by histology or cytology (HER-2 expression positive refers to the patients with no less than 10% tumor cells with immunohistochemical staining intensity of 2 + and confirmed by fluorescence in situ hybridization [fish], or immunohistochemical staining intensity of 3 + [color intensity range 0-3]); 3. The decision-making plan of clinicians includes pyrrolidine; 4. Patients whose clinical data can be traced.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients who could not understand the study or failed to sign the informed consent form; 3. Patients without follow-up data; 4. Other patients who are not suitable for the study;

Design outcomes

Secondary

MeasureTime frame
Overall Survival;Objective Response Rate;Duration of Response;Clinical Benefit Rate;Quality of Life;Compliance;

Primary

MeasureTime frame
Progression Free Survival;Adverse Events;

Countries

China

Contacts

Public ContactHuihui Li

Shandong Cancer Hospital and Institute

15553103209@163.com+86 15553103209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026